TRUALTBSETrualt Bioenergy LtdMediumNeutral
Announced Fri, 22 May · 17:10 IST

Investor Presentation for the Audited Financial Results for the quarter and year ended March 31, 2026.

Order Pipeline DisclosedInvestor Communications View source PDF

TRUALT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-0.3%1-day move
₹494.50
prior close
₹440.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.0-0.5-0.7-1.7-0.3-0.3-1.7+0.2+2.9+2.1+0.5-6.1-14.8
Up moveDown movePending
AI summary

TruAlt Bioenergy reported FY26 standalone total income of ₹1,772.94 Cr (down 8.64% YoY), with PAT declining 43.09% to ₹80.03 Cr. Q4 FY26 standalone revenue fell 32.46% YoY to ₹616.62 Cr. The ethanol segment faced significant headwinds with OMCs sharply reducing lifting despite full operational capacity, causing severe underutilisation across the sector. The company completed dual-feed integration (1,300 KLPD of 2,000 KLPD capacity) transitioning toward year-round operations. A ₹1,062 crore pending allocation (~15 crore litres) was secured via Karnataka High Court order. CBG segment showed strong growth with PAT up 185% YoY to ₹18.06 Cr for FY26. The company operates 5 ethanol units (2,000 KLPD), 1 operational CBG plant with 4 under construction, and 7 retail fuel outlets (4 under construction).

Likely market impact

The stock faces pressure from weak ethanol offtake and declining profits, though the court victory for ₹1,062 crore pending allocation and strong CBG growth provide recovery potential. Higher blending targets (E22-E30) and policy tailwinds should support long-term demand.